The UK and US have hammered out a important trade agreement that will preserve zero levies on UK drug products entering the American market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has committed to increase funding on medicines through the NHS. This move secures that import taxes on these vital products will stay at nothing for a timeframe of three years.
This agreement comes after earlier threats to significantly raise duties on patented pharmaceutical imports, with potential rates floated reaching 100%.
"This agreement with the United Kingdom bolsters the worldwide climate for innovative medicines and introduces much-needed equity to transatlantic medicine commerce," a statement noted.
Commercial Significance
Medicines represent one of the UK's most significant goods shipped to the US, which is clearly the biggest destination for large UK drugmakers.
Statistics show that in the one-year period prior to last September, the UK sold medicines totaling £11.1bn to the US. This figure made up nearly one-fifth of all goods exports in that period.
"This deal safeguards employment, stimulates investment and paves the way for the UK to become a international leader for biotech and pharma," a minister stated.
Specific British Pledges
The deal includes several key pledges from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it considers new treatments to be unaffordable by twenty-five percent.
- Higher Drug Budget: There is a goal to raise overall public funding on medicines from 0.3 percent of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The amount manufacturers must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates exceeded twenty percent.
Broader Context
The pact comes amid a long-running row between the sector and the ministers over drug pricing and approval rates.
This friction were heightened by claims that American customers were charged several times more for the equivalent treatments than consumers in the UK and Europe.
Recently, several large pharmaceutical investments in the UK have been delayed or cancelled, while multi-billion-dollar expansions have been pledged toward US facilities.
One official stated that the NHS had to spend more on medicines, noting that its spending on drugs had declined as a share of its total funding over the past decade.
